Data from the MTD has the potential to navigate strategy for the planned Phase 3 study in the U.S. and other major markets. The Company plans to file a Biologics License Application (BLA) for OCU400 in 2025. Ocugen is committed to finding...
Methods : The multicenter phase 1/2 open-label trial was a 3+3 dose escalation and dose expansion study. Participants included adults with autosomal recessive NR2E3 (AR-NR2E3), autosomal dominant NR2E3 (AD-NR2E3), or autosomal dominant RHO RP (AD-RHO). Sentinel subjects had a best-...
C-suite Biotech A Bright Spot for Female Founders Amid DEI Pullback March 6, 2025 · 2 min read · Annalee Armstrong Legal Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory March 6, 202...